Ulcerative Colitis Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Eli Lilly, AbbVie, Pfizer, Arena Pharma, Janssen

Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 110+ key pharma and biotech companies are working on 110+ pipeline drugs in the Ulcerative Colitis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Ulcerative Colitis Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Ulcerative Colitis Market

The Ulcerative Colitis Pipeline report embraces in-depth commercial, regulatory, and Ulcerative Colitis clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Ulcerative Colitis drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Ulcerative Colitis Pipeline Analysis

The report provides insights into: 

The report provides detailed insights into the emerging therapies for Ulcerative Colitis treatment and the aggregate therapies developed by major pharma companies.

It accesses the different Ulcerative Colitis therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

It outlines the major Ulcerative Colitis companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

The report evaluates the Ulcerative Colitis drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Ulcerative Colitis therapeutic market.

Analysis of Emerging Ulcerative Colitis Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) 

Pre-clinical and Discovery stage candidates

Discontinued and inactive candidates

Route of Administration

The Ulcerative Colitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as






Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody



Small molecule

Gene therapy

Learn How the Ulcerative Colitis Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @


Ulcerative Colitis Therapeutics Landscape

Several major pharma and biotech companies are developing therapies for Ulcerative Colitis. Currently, Gilead Sciences is leading the therapeutics market with its Ulcerative Colitis drug candidates in the most advanced stage of clinical development.

Ulcerative Colitis Companies Actively Working in the Therapeutic Market Include:

Eli Lilly and Company, Lipid Therapeutics, Hoffmann-La Roche, Arena Pharmaceuticals, InDex Pharmaceuticals, EA Pharma, Theravance Biopharma, Boehringer Ingelheim, Janssen Research & Development, Lycera, LG Chem, Iltoo Pharma, Immunic, Hutchison Medipharma, Tianjin Hemay Pharmaceutical, GlaxoSmithKline, Galapagos, Celgene, Gossamer Bio, Eisai, UCB, Suzhou Connect Biopharmaceuticals, Landos Biopharma, Seres Therapeutics, Abivax, Genentech, ParaTech A/S, I-Mab Biopharma, Sublimity Therapeutics Holdco, Reistone Biopharma, Qu Biologics, PurGenesis Technologies, Protagonist Therapeutics, Pfizer, Palobiofarma, Novartis Pharmaceuticals, Bristol-Myers Squibb, Bridge Biotherapeutics, Amgen, Allergan, Applied Molecular Transport, AbGenomics International, Protalix BioTherapeutics, LTT Bio-Pharma Co Ltd, Dongwha pharma, Seres Therapeutics, Innovation Pharmaceuticals, Holy Stone Healthcare, SLA Pharma, OSE Immunotherapeutics, Bridge Biotherapeutics, Mitsubishi Tanabe Pharma, Sterna Biologicals, Mesoblast, Oncostellae, First Wave Bio, Oppilan Pharma, NeuClone, Morphic Therapeutic, Metacrine, LG Chem, Koutif Therapeutics, Kiniksa Pharmaceuticals, Avaxia Biologics, Algernon Pharmaceuticals, Akeso Biopharma, Kaleido Biosciences, Rebiotix, Prometheus Biosciences, PNB Vesper Life Science, Pandion Therapeutics, Palatin Technologies, Theravance Biopharma, VHsquared, Seres Therapeutics, Hoffmann-La Roche, Provention Bio, Bacainn Therapeutics, Landos Biopharma, Bristol-Myers Squibb, Janssen Research & Development, GlaxoSmithKline, Assembly Biosciences, NuBiyota, and many others.

Emerging and Marketed Ulcerative Colitis Drugs Covered in the Report Include:

Etrasimod: Pfizer

Skyrizi (Risankizumab): AbbVie

Mirikizumab (LY-3074828): Eli Lilly and Company

Etrasimod: Arena Pharmaceuticals

Tremfya (Guselkumab): Janssen (Johnson & Johnson)

SHR0302: Reistone Biopharma

BT-11: Landos Biopharma

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Ulcerative Colitis Companies Working in the Market @ 


Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Ulcerative Colitis Treatment Patterns

4. Ulcerative Colitis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Ulcerative Colitis Late Stage Products (Phase-III)

7. Ulcerative Colitis Mid-Stage Products (Phase-II)

8. Ulcerative Colitis Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Ulcerative Colitis Discontinued Products

13. Ulcerative Colitis Product Profiles

14. Major Ulcerative Colitis Companies in the Market

15. Key Products in the Ulcerative Colitis Therapeutics Segment

16. Dormant and Discontinued Products

17. Ulcerative Colitis Unmet Needs

18. Ulcerative Colitis Future Perspectives

19. Ulcerative Colitis Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @




About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Down Syndrome Market

“Down Syndrome Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Down Syndrome market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Down Syndrome market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.


Smart public opinion research for everyone.

%d bloggers like this: